ZIM
MCRB icon

Zacks Investment Management’s Seres Therapeutics MCRB Stock Holding History

Zacks Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-543
Closed -$82K – 556
2018
Q3 		$82K Hold
543
– – ﹤0.01% 510
2018
Q2 		$93K Hold
543
– – ﹤0.01% 532
2018
Q1 		$80K Hold
543
– – ﹤0.01% 508
2017
Q4 		$110K Sell
543
-60
-10% -$12.3K ﹤0.01% 553
2017
Q3 		$194K Buy
+603
New +$165K ﹤0.01% 530

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Zacks Investment Management's MCRB Position: Q4 2018 in Review

Zacks Investment Management sold out of Seres Therapeutics (MCRB) in Q4 2018, closing a stake of 543 shares — an estimated $82K sold.

Zacks Investment Management first reported a position in MCRB in Q3 2017 and held it in 5 quarters. The position peaked at $194K in Q3 2017. 70 funds tracked by Wall St. Rank hold MCRB as of Q4 2018.

  • Zacks Investment Management reported no remaining Seres Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Zacks Investment Management sold 543 Seres Therapeutics shares in Q4 2018, an estimated $82K.
  • Zacks Investment Management first reported a position in Seres Therapeutics in Q3 2017 and held it in 5 quarters.
  • Zacks Investment Management's Seres Therapeutics position peaked at $194K in Q3 2017.
  • 70 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2018.

Based on Zacks Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.